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Abstract
Background: The 516G > T polymorphism in exon 4 of the CYP2B6 gene has been associated with increased
plasma Efavirenz (EFV) concentrations. EFV concentrations greater than the recommended therapeutic range have
been associated with the increased likelihood of developing adverse CNS effects. The aims of this study were to a)
determine the presence of the 516G > T and other CYP2B6 exon 4 polymorphisms in a South African group of HIV-
infected individuals b) investigate the relationship between the EFV plasma concentrations, the CYP2B6 516G > T
polymorphism and the occurrence of CNS related side effects in this group of patients and c) develop and validate
a rapid method for determination of EFV in plasma.
Method: Data from 80 patients is presented. Genetic polymorphisms in exon 4 of the CYP2B6 gene were identified
using PCR amplification of this region followed by sequencing of the amplification products. EFV concentrations
were analysed by UPLC-MS/MS. Assessment of the presence of CNS related side effects following EFV initiation
were elicited with the use of a questionnaire together with physical examination.
Results: Plasma EFV concentrations displayed high inter-individual variability amongst subjects with concentrations
ranging from 94 μg/l to 23227 μg/l at 2 weeks post initiation of treatment. For the 516G > T polymorphism the
following frequencies were observed 23% of patients were TT homozygous, 36% GG and 41% GT. The TT
homozygous patients had significantly higher EFV concentrations vs. those with the wild (GG) genotype (p < 0.05).
Patients who experienced no side effects had significantly lower EFV plasma concentrations vs. the group of
patients which experienced the most severe side effects (p < 0.05).
Conclusion: The significant association between the 516G > T polymorphism and plasma EFV concentrations has
been demonstrated in this study. A rapid and sensitive method for the measurement of plasma EFV concentration
was developed and validated.
Background
Sub-Saharan Africa bears the greatest burden of HIV
infection worldwide with data estimating that one in
five adults between the ages of 15-49 years is infected
[1]. Currently over 400 000 patients receive anti-retro-
viral (ARV) therapy at South African state hospitals [1].
Efavirenz (EFV), a non- nucleoside reverse transcriptase
inhibitor (NNRTI), forms part of the first line therapy
for many of these HIV infected individuals. The ARV
experience is relatively new to South Africa in compari-
son to many developed nations and studies looking at
adverse effects of treatment and long-term treatment
complications are only now beginning to emerge. Clini-
cal trials have reported central nervous system (CNS)
side effects in >50% of patients following commence-
ment of EFV therapy [2]. However no studies in South
Africa have investigated EFV plasma concentrations and
the incidence of CNS related side effects. The reported
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cinations, acute mania and psychosis [2]. In patients
commencing therapy for the first time, the development
of adverse effects may negatively influence adherence
and treatment success. Previous studies have shown that
plasma EFV concentrations display a large between sub-
ject variability with a coefficient of variance (CV) of up
to 118% [3]. Prediction of therapeutic efficacy and the
likelihood of developing adverse CNS effects have been
associated with plasma EFV concentrations [3,4].
Patients with EFV concentrations of > 4000 μg/l may
experience neurological adverse effects more frequently,
whilst those with plasma concentrations < 1000 μg/l
appear to have a greater risk for emergence of selective
drug resistance and treatment failure [3].
The reasons for inter-individual variability in terms of
drug related toxicity, drug concentrations and drug effi-
cacy are multifactorial and include differences in gender
metabolism, drug compliance, presence of underlying
diseases, use of concomitant medications as well as
genetic factors [5]. Genetic differences among indivi-
duals influence metabolism, distribution and elimination
of drugs. EFV is primarily metabolised by the cyto-
chrome P450 isoenzyme CYP2B6 in the liver [6]. The
CYP2B6 gene has been mapped to chromosome 19 [7].
It is 28 kb long and consists of 9 exons [7]. The pre-
sence of several polymorphisms present in the gene cod-
i n gf o rt h ee n z y m em a yi n f l u e n c ed r u gm e t a b o l i s m .
Previous studies have shown that the allelic variant
516G > T (located in exon 4) is associated with dimin-
ished activity of the CYP2B6 isoenzyme, increased
plasma EFV concentrations together with increased inci-
dence of EFV associated neuropsychological toxicity
[4,8]. Rotger et al identified significant correlations
between the presence of the TT genotype and higher
intra and extracellular EFV concentrations and between
the presence of the single nucleotide polymorphism
(SNP) and increased incidence of fatigue, mood and
sleep disorders post initiation of EFV [9]. The allelic var-
iant 516G > T was also shown to have increased preva-
lence amongst African Americans with studies quoting
the frequency of this allele as 30-38% [4,10]. Studies in
African populations indicate prevalences varying
between 36-60% [10-12].
The aims of this study were three-fold 1) to investi-
gate and describe polymorphisms present in exon 4 of
the CYP2B6 gene in black HIV infected individuals 2) to
investigate the relationship between the EFV plasma
concentrations and the presence of CYP2B6 exon 4
SNPs with the occurrence of CNS related side effects in
this group of patients and 3) develop and validate a
rapid method for determination of EFV concentrations
in plasma to enable monitoring of drug concentrations
in HIV-infected patients.
Materials and methods
Sample collection
Participants were recruited from Black South African
patients attending the ARV clinic at the Charlotte Max-
eke Johannesburg Academic Hospital. Informed consent
was obtained from all participants enrolled in the study.
E t h i c a la p p r o v a lf o rt h es t u d yw a so b t a i n e df r o mt h e
Research Ethics Committee, Faculty of Health Sciences,
University of the Witwatersrand.
Participants included in the study were all treatment
naïve, adult patients who were initiated on the triple
therapy regimen of EFV, stavudine and lamivudine. All
patients received the same dosage of 600mg EFV nightly.
It is the general practice at the ARV clinic to not pre-
scribe EFV for any patients with a current or previous
psychiatric condition requiring medication or hospitalisa-
tion. At the follow up visit 2 weeks post initiation of ther-
apy blood samples were collected. The time interval of
two weeks was chosen as plasma EFV concentrations
take 6-10 days to achieve steady state concentrations [2].
It was also to ensure better recall of side effects experi-
enced by patients following initiation of ARVs.
Time of last dose was obtained by patient report.
Patients who had not taken their EFV the night before
or those who had missed more than two doses were
excluded from the study. The use of concomitant drugs
and herbal medications (refer to List below for further
information and exclusion criteria) which are known to
influence plasma EFV concentrations were excluded
w i t ht h ea i do fav e r b a lq u e s t ionnaire administered to
all possible participants, prior to enrolment into the
study. Patients, who were pregnant, had evidence of
hepatic dysfunction or reported significant alcohol con-
sumption were also not included in the study. Samples
from 100 patients were used. Liver function tests, viral
load and CD4 analyses are performed routinely on all
patients commencing ARV therapy at the clinic.
List of exclusion criteria
Pregnancy or breast feeding
Previous or current psychiatric disease being treated
by a medical practioner
Non compliance (missed more than 2 doses in one
month)
Alcohol intake >4 units/day for male and > 3 units/
day in females (1 unit = 8 g of alcohol) [13]
Patients taking drugs that potentially may interact
with EFV metabolism (i.e Rifampicin, Ritonavir, Carba-
mazepine, Phenytoin, phenobarbitone, St John’s Wort)
Hepatic dysfunction as indicated by:
a) Transaminases > 5-10× the upper limit of normal
b) ALP> 5-10× the upper limit of normal
Gounden et al. AIDS Research and Therapy 2010, 7:32
http://www.aidsrestherapy.com/content/7/1/32
Page 2 of 9c) Total bilirubin > 2.5-5× the upper limit of
normal [14]
K-EDTA samples were collected from patients
2 weeks after initiation of Efavirenz
The samples were separated by centrifugation at 5000
g for 10 minutes (immediately) after collection. Buffy
coats were stored at -20°C until DNA extraction and
plasma samples were stored at -70°C until the analysis
for EFV levels was performed.
Analysis of Plasma Efavirenz concentrations
EFV was analyzed by Ultra Performance Liquid Chro-
matography Quatro micro (UPLC-MS/MS), (Waters,
Massachusetts, USA). Samples were extracted using
solid phase Weak Cation Exchange cartridges (WCX,
Oasis-Microsep, Massachusetts, USA). 200 μlo fp l a s m a
was used for analysis of the drug concentrations. Chro-
matographic separation was performed on an Acquity,
(Waters, Massachusetts, USA) phenyl column 1.7 μm
(2.1 × 50 mm). The chromatographic column used was
stable for > 200 injections. The mobile phase consisted
of A: B at a ratio of 30:70 (2 mM ammonium acetate
with 1% formic acid: 100% Acetonitrile (ACN)) this was
run on a gradient with the analyte eluting within
1.5 min. The column temperature was maintained at
50°C throughout the runs. Injection volume for each
sample was 10 μl.
The instrument was operated in Electron spray ioniza-
tion positive (ESI+) mode. The MRM transition used for
EFV was m/z (mass to charge ratio) [M
+ACN
+H]
+ 357.7
> 316.3. Retention time was 0.72 min with total run
time of 2 min.
A standard EP10 evaluation [as per Clinical and
Laboratory Standards Institute (CLSI) protocol] to assess
recovery, assay precision and linearity was performed for
validation. This protocol examines specific performance
parameters such as linearity, carryover, bias and recov-
ery [15]. Commercially available calibrator standards
and controls were used (Chromosystems Instruments
and Chemicals GmbH, Munich, Germany). Calibration
curves and controls were run with every batch of patient
specimens. The correlation coefficient of the standard
curves obtained on multiple days was consistently
≥ 0.98 (n = 18). Separated specimens were stable at
3 months stored at -70°C. No changes were observed in
plasma that had been subjected to two freeze-thaw
cycles.
Assessment of EFV-related side effects
Prior to treatment initiation all patients were assessed
by a medical doctor to determine the presence of any
baseline neuropsychiatric symptoms. Features that
were looked for included a previous history of a
psychiatric complaint as well as current presence of
suicidal ideation, delusions or psychosis. A general
neurological exam was also performed on possible
participants.
A questionnaire (refer to Additional file 1) adapted
from one used in the AIDS Clinical Trials Group study
A5095 was administered to all participants at the 2
week follow up post EFV initiation [16]. Responses were
scored in terms of frequency of side effects (such as
headache, dizziness and other neuropsychological side
effects associated with EFV use) experienced and sever-
ity in terms of effect on daily activities (severity was
scored ranging from no effect on daily activities to
unable to carry out daily activities). The maximum score
that could be obtained was 72 points. Based on their
questionnaires, subjects were grouped into those with
no side effects (Group1), those with mild symptoms (1-
12 points-Group2), with moderate symptoms (13-48
points -Group3) and with severe side effects (> 48
points or presence of hallucinations or psychotic epi-
sodes-Group 4). At the same visit the patients were also
examined by a medical doctor for any clinical signs or
symptoms of the neuropsychiatric and other EFV related
side effects. Patients’ clinic files were reviewed post 1
month follow-up to determine the persistence of neu-
ropsychiatric symptoms as per patient complaints and
physician assessment
Further follow up
Viral loads for participants at 3 or 6 months post initia-
tion of therapy were also reviewed using our laboratory
information system. A successful viral load response was
defined as a viral load below the detection limit of
50 copies/ml.
Analysis of SNPs
Subjects were genotyped for CYP2B6 516G > T
(rs3745274). DNA extraction was performed using Invi-
sorb Blood Mini Kit (Invitek, Germany). Forward
(5′-TGTTGTAGTGAGAGTTCAATG-3′)and reverse
(5′-CTATCCCTGTCTCACCGTC-3′)p r i m e r sf o re x o n
4 were designed using the published gene sequence on
GenBank (accession number NM 000767) together with
the software programme GeneRunner version 3.05
(Hastings Software Inc.). Patient sequences were ampli-
fied using conventional PCR. PCR products were run on
agarose gels together with 50 bp DNA molecular weight
marker (Generuler; Fermentas, Lithuania) and a negative
control to detect any possible contamination. Amplicons
were sequenced by Inqaba Biotech (South Africa).
Sequencing was performed using a Spectrumedix SCE
400 Genetica analysis system (Spectrumedix LCC, USA).
Sequences were analysed using the Sequencher program
version 4.1.4 (Genecodes, USA).
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The sample size (n = 54) required to detect significant
differences in EFV concentrations across the different
genotypes with a statistical power of 0.90 was deter-
mined. The parameters for an a level (Type 1 error)
and effect size were 0.05 and 0.5, respectively. Sample
size calculation was performed using the G*Power pro-
gram, version 3.1.2 (Universität Kiel Dusseldorf,
Germany).
The Chi-squared test for the assessment of Hardy-
Weinberg equilibrium for the analyzed SNP was per-
formed using software on the Online Encylcopedia for
Genetic Epidemiology Studies [17]. All other statistical
analyses were conducted using the Statistica program,
version 8 (Statsoft, Tulsa, USA). Data was assessed to be
parametric using the Shapiro-Wilks W test. One way
Kruskal Wallis ANOVA was used to compare EFV con-
centrations as well as follow-up viral loads across the
three genotypes. Spearmen rank order correlation was
used to assess the relationship between EFV concentra-
tions and follow-up viral loads.
Multivariate regression analysis was used to demon-
strate the relationship between possible confounding
variables BMI, age, CD4 count, viral loads and sampling
times on plasma EFV concentrations.
Results
Data for 80 patients were analysed. Twenty patients
were excluded due to insufficient plasma volumes for
UPLC-MS/MS analysis (n = 1), poor DNA yields follow-
ing extraction (n = 10) or technical problems with
regards to sequencing (n = 9).
The main characteristics of the study cohort are sum-
marised in Table 1.
The genotype distribution and EFV concentrations
were as follows: 36% (n = 29) of patients were homozy-
gous GG for the CYP2B6 516G > T polymorphism with
median EFV plasma concentration of 2260 μg/l (range
94 μg/l to 12957 μg/l); 23% (n = 18) of patients were
characterised as homozygous TT,h a dam e d i a nE F V
concentration of 7136 μg/l (range 1334 μg/l to 23227
μg/l); 41% (n = 33) of patients were heterozygous GT
for the polymorphism with a median EFV concentration
of 3857 μg/l (range 184 μg/l to 15581 μg/l). The fre-
quency of the 516G > T allele was 43% in our study
population. The observed genotype frequency was in
Hardy-Weinberg equilibrium
Plasma EFV concentrations in patients ranged from 94
μg/l to 23227 μg/l (median 3980 μg/l), confirming the
high inter-individual variability previously noted in
patients receiving EFV therapy [3,12]. Only 51% of
patients had EFV concentrations within the recom-
mended concentration range of 1000 μg/l to 4000 μg/l
[3]. 9% of patients had levels below 1000 μg/l. Interest-
ingly, most (61%) of those who were homozygous GG
for the 516G > T polymorphism had EFV concentra-
tions within the therapeutic range, whilst only 16% of
those with the TT genotype had concentrations within
this range. Plasma EFV concentrations were analysed
across genotype groups using a Kruskal-Wallis ANOVA.
This demonstrated that patients who were homozygous
TT for the 516G > T polymorphism in exon 4 had sig-
nificantly higher EFV concentrations vs. those patients
with the GG or GT genotype (p < 0.05) (refer to Figure
1). The average time between last dose of EFV taken by
patients and sample collection was 14.6 ± 1.5 hours.
Using simple regression EFV plasma concentrations dis-
played no significant correlation with sampling times
Table 1 Baseline characteristics and summary of findings from data of the 80 patients analysed in the study
Variable All GG GT TT
Age (years) 37.5 (SD:9.0),(n = 80) 38.0 (SD:8.5),(n = 29) 37 (SD:9.0),(n = 33) 33.5 (SD:10.2),(n = 18)
Sex Male: 20 Female: 60 Male: 8 Female:21 Male:7 Female:26 Male: 5 Female:13
BMI (kg/m
2) 22.6 (SD: 3.6),(n = 80) 22.4 (SD:3.9), (n = 29) 23.2 (SD:3.4), (n = 33) 22 (SD:3.0),(n = 18)
Initial CD4 count (×10
6 l) 128.5 (IQR:142),(n = 80) 113 (IQR:114),(n = 29) 131(IQR:148),(n = 33) 158 (IQR:9),(n = 18)
Initial viral load(copies/ml) 86450 (IQR:2.3 × 10
6),
(n = 76)
96600 (IQR:2.2 × 10
6),
(n = 27)
84900 (IQR:2.4 × 10
6),
(n = 33)
86500 (IQR:2.1 × 10
6),
(n = 16)
Presence of side effects(%) 84 (n = 67) * 76 (n = 22) 85 (n = 28) 94 (n = 17)
EFV concentrations (μg/l) 3980 (IQR:4476),(n = 80)* 2260 (IQR:3411),(n = 29) ** 3858(IQR:2385),(n = 33)** 7136(IQR:3623),(n = 18)**
IQR: interquartile range
n = number
BMI = Body mass index
Parametric data displayed as mean (1SD), non-parametric data displayed as median (IQR)
* p value (< 0.05) for Spearmen correlation between EFV plasma concentrations and the presence of side effects (dependent variable)
** p value (< 0.05) for ANOVA analysis of EFV concentrations across genotypes for TT vs. GT/GG
Side effects as per questionnaire score
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2 = 0.0009) (Refer to Figure 2). Multivariate regression
analysis also demonstrated that sampling times as well
age, BMI, initial CD4 counts and viral loads did not sig-
nificantly correlate with EFV concentrations of patients
(R
2 = 0.107, p = 0.23).
85% of patients experienced some form of EFV-related
side effect. The majority of patients, who had experi-
enced side effects following initiation of Efavirenz ther-
apy, had mild symptoms with dizziness (55%) and
headache (45%) as the two most frequent complaints.
No patients reported suicidal ideation whilst only 5% of
patients reported having experienced hallucinations fol-
lowing initiation of EFV therapy. Statistical analysis by
Spearmen rank order correlation exhibited a significant
correlation (p < 0.05) between questionnaire scores and
EFV concentrations amongst participants. The patients
who experienced no side effects had a significantly
(Analysis by Kruskal Wallis ANOVA p < 0.05) lower
median EFV plasma concentration of 2666 μg/l (concen-
trations ranged from 102.3 μg/l to 4839.7 μg/l) com-
pared to the group which experienced the most severe
side effects with a median EFV plasma concentration of
14882 μg/l (concentrations ranged from 9825 μg/l to
23227 μg/l). Refer to Figure 3 for side effect scores as
per questionnaire for each genotype. 33% (7 of 21) of all
patients who reported severe and moderate EFV related
side effects carried the TT genotype. Patients homozy-
gous for the CYP2B6 516G > T showed increased over-
all side effects as compared to those displaying the wild
type genotype. However this difference was not statisti-
cally significant when Kruskal Wallis ANOVA was per-
formed across the genotypes (p = 0.08). At the 1-month
follow-up visit following initiation of therapy, the speci-
fic EFV-related side effects had resolved for all patients
involved in the study.
We also analysed patient sequences for the presence
of other exon 4 SNPs found within the CYP2B6 gene
namely 503C > T (rs36056539), 593T > C (rs36079186),
499C > G (rs3826711), 546C > G (rs45459594) and
547G > A (rs58871670). None of these polymorphisms
were detected amongst our cohort.
Kruskal-Wallis ANOVA showed no significant correla-
tion (p = 0.32) between the GG, TT and GT genotypes
and follow up viral loads (performed at 3 or 6 months
post initiation of therapy). Spearmen correlation also
showed no significant (p = 0.10) relationship between
the two week EFV plasma concentrations and the follow
up viral loads. 15% (11 of 72 patients for which records
of follow up viral loads were available) of patients had
viral loads above the detectable limit. These 11 patients’
viral loads ranged from 110 to170000 copies/ml. Only 1
of these patients had an EFV concentration lower than
Figure 1 Dot plot of EFV plasma concentrations by CYP2B6-516 genotype. GG, homozygous wild-type; GT, heterozygous genotype, TT
homozygous genotype. –Value between dashed lines represents therapeutic range.
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grouped into those with no side effects (Group1), those with mild symptoms (1-12 points- Group2), with moderate symptoms (13-48 points
-Group3) and with severe side effects (> 48 points or presence of hallucinations or psychotic episodes-Group 4). Please refer to text for further
detail. GG (n = 29): 24% (n = 7) no side effects reported; 59% (n = 17) mild side effects; 17% (n = 5) moderate side effects; none with severe
side effects. GT (n = 33): 15%(n = 5) no side effects; 55% (n = 18) mild side effects; 27% (n = 9) moderate side effects; 3% (n = 1) severe side
effects TT (n = 18): 5% (n = 1) no side effects; 56% (n = 10) mild side effects; 28% (n = 5) moderate side effects. 11% (n = 2) severe side effects.
(Refer appendix for patient questionnaire).
Figure 2 Plot of EFV plasma concentrations against sampling times.R
2 value of 0.0009 indicates no correlation between sampling times
and EFV plasma concentrations of patients involved in the study.
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these eleven patients had plasma EFV concentrations
above the recommended therapeutic range on initial
measurement
In terms of method characteristics for the UPLC-MS/
MS: the extraction efficiency/recovery ranged from 83-
118%, with a mean recovery following extraction 101%.
The assay was linear up to a concentration of 30630 μg/
l. The limit of detection (LOD) for the assay is 85 μg/l
and the limit of quantitation (LOQ) is 101 μg/l. Intra-
assay and inter-assay precision CV’sr a n g e df r o m2 . 8t o
10%, and 8 -8.9%, respectively. Analysis showed no sig-
nificant carryover or drift
Discussion
This study revealed the prevalence of the allelic variant
CYP2B6 TT (poor metabolisers) to be 23% amongst our
study population. The percentage is very similar to the
Adult AIDS Clinical Trials Group study by Haas et al,
which reported a 20% prevalence of the TT genotype
amongst their African-American cohort [4]. The authors
of the current study also observed the statistically signif-
icant (p < 0.05) relationship between the occurrence of
severe EFV related side effects and increased plasma
concentrations of the drug.
Gatananga et al showed that those patients with the
CYP2B6 516G > T SNP had significantly higher plasma
EFV concentrations (> 6000 μg/l) on the standard dos-
ing regimen [18]. In that study the reduction of the
initial EFV dosages to either 400 mg or 200 mg resulted
in lowering of EFV concentrations towards the thera-
peutic range and an improvement in CNS related symp-
toms in the majority of these patients. In our study, the
median EFV concentration for the TT homozygotes was
7136 μg/l. It would have been interesting to note,
whether in our population, a decrease in dosage would
have had a similar effect.
None of the other published SNPs (as mentioned
earlier) in exon 4 of the CYP2B6 gene were detected in
patients from this study. These results are similar to
t h ef i n d i n g so fas t u d yw h e r et h ef r e q u e n c yo ft h e
503C > T allele was found to be 0% and 2.5% amongst
African Americans and Ghanaians, respectively [10].
Both the 503C > T and 593T > C polymorphisms are
associated with amino acid changes but their clinical
association with EFV concentrations has not been fully
elucidated.
In this study a significant relationship was found
between the 516G > T SNP, plasma EFV concentrations
and increased reporting of CNS side effects. However all
patients denied persistence of the CNS symptoms at the
4w e e kf o l l o w - u p- p o s ti n i t i a t i o no ft h e r a p y .I ti sl i k e l y
that those with the 516G > T allele still had high plasma
EFV concentrations despite improvement of symptoms.
Haas et al reported increased plasma EFV concentra-
tions in patients with this SNP at 24 weeks post initia-
tion [4]. However in that study, increased CNS
symptoms were only reported during the first week fol-
lowing treatment commencement and thereafter
patients seemed to develop a tolerance to these side
effects despite continued high EFV concentrations.
Fumaz et al, in a long term follow up of patients receiv-
ing EFV therapy demonstrated that more than 50% of
the patients had persistent though mostly mild neurop-
sychiatric symptoms [19]. The presence of other factors
associated with the CNS side effects as well as the ade-
quacy of assessment of neuropsychological side effects,
needs to be examined [20].
The relationships between drug efficacy and lower vir-
ological failure rates when optimal drug concentrations
are achieved have been demonstrated in a number of
studies [3,8,10]. Repeated exposure to sub-therapeutic
concentrations of EFV also increases the chance for the
development of resistant viral strains and thus treatment
failure [21]. The long half-life of EFV suggests that
treatment interruption in patients carrying the TT geno-
type also selects for EFV resistance due to sub-therapeu-
tic concentrations for extended periods [22]. EFV
resistance appears to be relatively common. The K103N
mutation associated with EFV resistance was identified
in 25% of HIV infected patients with drug resistance in
a recent study performed in Johannesburg [23]. In our
study 9% of patients had EFV concentrations below the
therapeutic minimum of 1000 μg/l which would be a
risk for development of EFV resistance in these patients.
TDM could be useful in identifying these patients with
a view to optimising treatment by either increasing EFV
dosages, changing to alternate regimens or identifying
non compliance. Poor adherence must also be consid-
ered as a cause of sub-therapeutic EFV concentrations
in patients. Unfortunately in this study we were only
able to assess compliance by patient report, which is
often inaccurate and unreliable. Follow up of patient
viral load at 3 or 6 months indicated that for the major-
ity of patients initial EFV concentrations had no signifi-
cant effect on viral suppression. It is possible that
patients may achieve adequate viral load suppression on
lower doses of EFV than are currently prescribed. How-
ever, in this study information regarding change in
treatment regimens and patient adherence were not
readily available post the one month follow up period of
this study. Longer follow-up studies should be done to
test this hypothesis.
There are limitations to our study. One limitation is
that genotyping for other significant polymorphisms
affecting EFV metabolism were not performed. The pre-
sence of the CYP2B6 983 T > C, although less fre-
quently found in African populations, has also been
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[24]. Other SNPs in genes coding for metabolizing
enzymes such as CYP2A6, and UGT2B7 have been asso-
ciated with increased EFV concentrations [25,26]. Phar-
macokinetics has shown that trough concentrations of
drugs are the most useful in assessing efficacy and toxi-
city of the drug. The nighttime dosing of EFV results in
difficulty obtaining trough doses. The suggested thera-
peutic range of 1000 - 4000 μg/l is not based on trough
concentrations but on concentrations 8-20 hours post
dosing [3]. Lopez et al demonstrated that trough levels
are not estimated with sufficient accuracy when blood
samples taken at 8, 12 and 16 hours post dosage were
used. This is despite the close linear relationship
between plasma EFV concentrations at these time points
and trough concentrations [27]. Evidence for the use of
this therapeutic range in assessing the relation between
treatment efficacy and EFV plasma concentrations has
been weak in other studies [28-31]. Twenty percent of
participants enrolled in the study were not included in
the final analysis. This was largely due to problems with
DNA extraction and genotyping. A possible introduction
of bias may have occurred by not being able to include
data from these patients in the final analyses, although
the final sample size obtained was adequately powered.
In nations like South Africa where the goal of ade-
quate access to antiretroviral therapy for all HIV-
infected patients is still to be achieved, the added
expense of pharmacogenomic genotyping and TDM
may seem unrealistic. TDM for EFV using a LCMS/MS
methods such as that described in this study allows for
accurate measurements and high throughput with a run
time of only two minutes. However the evidence that
genotyping and measurement of EFV plasma concentra-
tions actually improve patient outcome is lacking.
Furthermore in this study, patients’ EFV related side
effects resolved within a month and there was no signifi-
cant correlation between patients follow up viral loads
and their plasma EFV concentrations. In view of this the
authors feel that TDM for EFV therapy may have a role
in assessment of patient adherence. However our find-
ings suggest that use of TDM does not improve patient
outcomes and larger longitudinal studies are required
before a final recommendation can be made with
regards to routine implementation of TDM in South
African HIV infected patients receiving EFV therapy.
Additional material
Additional file 1: Side effect questionnaire. A copy of the
questionnaire used to assess the presence of neuropsychiatric side
effects post EFV initiation in study participants
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